Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.

CONCLUSION: Despite the open-label design of the data, improvements in multiple clinical outcomes were seen. The proportion of patients reaching ACR20 in the TICOPA study was higher than in the Methotrexate in Psoriatic Arthritis study (41% vs 34%), but no comparative data are available for other outcomes. There is a suggestion of a dose response, but this is hard to assess when patients doing well may be maintained on lower doses. PMID: 26669913 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26669913?dopt=Abstract

Source: J Rheumatol - December 15, 2015 Category: Rheumatology Authors: Coates LC, Helliwell PS Tags: J Rheumatol Source Type: research